Alliance acquires U.K. rights to three dermatology products from Pfizer

By Lisa Kerner

Charlotte, N.C., July 6 - Alliance Pharma plc said it acquired the U.K. rights to oral antihistamine Atarax, the oral steroid Deltacortril and Terracortril, a topical combination steroid, from Pfizer.

Atarax and Deltacortril had combined U.K. sales of £2.8 million for the 12 months ended in May.

Alliance plans to transfer the manufacturing and reformulate the products. The company will also pay a consideration to Pfizer for the next three years.

Deltacortril is used in the treatment of asthma, ulcerative colitis, rheumatoid arthritis and eczema. Alliance will relaunch Terracortril, which is used in burn units and has been off the U.K. market for more than a year.

"Our dermatology portfolio has been a key area of focus for Alliance during the past year so I am delighted by this acquisition of three important brands to expand our franchise," Alliance chief executive John Dawson said in a company news release.

"In addition to treating skin conditions two of these three products treat other indications and we look forward also to serving those treatment areas."

Alliance is a specialty pharmaceutical company based in Chippenham, Wiltshire, U.K.

New York City-based Pfizer develops and markets prescription and over-the-counter medicines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.